Testis Kanseri
Özet
Testis kanseri, hem özellikle genç erkeklerde görülmesi hem de tedaviyle büyük oranda kür sağlanabilmesi sebebiyle önem arz eden bir kanser türüdür. Erken evre hastalıkta beş yıllık sağkalım oranları %95’in üzerindedir. Ancak tedavi sonrası dönemde erken evre hastalıkta bile nüks oranı %30’lara kadar çıkabilmektedir. Bu sebeple hastaların düzenli takibi hayati önem taşımaktadır. Takibin en önemli amacı, olası nükslerin erken dönemde saptanıp hastalara kür şansı tanımaktır. Takibin önemi sadece nüksleri saptamakla sınırlı değildir. Testis tümörü tanısı almış genç hastalar, tedavi sonrası uzun yıllar yaşamaya devam etmektedirler ve bu süreçte tedavilerin uzun dönem yan etkileriyle karşılaşabilirler. Kardiyovasküler hastalıklar, ikincil kanserler, hipogonadizm, infertilite, kronik yorgunluk bunlara örnek olarak verilebilir. Dolayısıyla testis kanserli hastalarda takip, hem onkolojik nükslerin izlenmesini hem de hastaların uzun dönem sağlığının korunmasını hedeflemelidir. Sonuç olarak, tedavi sonrası takip; testis kanseri yönetiminin ayrılmaz bir parçası olup hastaların hem yaşam süresini hem de yaşam kalitesini artırmada kritik rol oynar.
Testicular cancer represents a malignancy of significant clinical relevance, owing to its predominance among young men and its high curability with appropriate treatment. In cases diagnosed at an early stage, five-year survival rates exceed 95%. Nevertheless, even among early-stage patients, recurrence rates may reach up to 30%, underscoring the critical importance of systematic surveillance. The principal objective of follow-up is the early detection of recurrences, thereby preserving the opportunity for curative intervention. Importantly, the role of surveillance extends beyond oncologic monitoring. Young survivors of testicular cancer are expected to live for decades after treatment and may experience a range of long-term sequelae associated with prior therapies. These include cardiovascular disease, secondary malignancies, hypogonadism, infertility, and chronic fatigue. Accordingly, follow-up in testicular cancer must encompass both the early identification of oncologic relapse and the proactive management of survivorship issues to optimize long-term health outcomes. In summary, post-treatment surveillance constitutes an essential component of testicular cancer care, contributing critically to both prolonged survival and the maintenance of quality of life.
Referanslar
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Annals of Oncology. 2022;33(4):362-375. doi:10.1016/j.annonc.2022.01.002
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820
Znaor A, Lortet-Tieulent J, Jemal A, Bray F. International Variations and Trends in Testicular Cancer Incidence and Mortality. Eur Urol. 2014;65(6):1095-1106. doi:10.1016/J.EURURO.2013.11.004
Sarici H, Telli O, Eroǧlu M. Bilateral testiküler germ hücreli tümörler. Turk Uroloji Dergisi. 2013;39(4):249-252. doi:10.5152/tud.2013.062
Del Risco Kollerud R, Ruud E, Haugnes HS, et al. Family history of cancer and risk of paediatric and young adult’s testicular cancer: A Norwegian cohort study. Br J Cancer. 2019;120(10):1007-1014. doi:10.1038/s41416-019-0445-2
Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology. 2018;29(8):1658-1686. doi:10.1093/ANNONC/MDY217
Auer T, De Zordo T, Dejaco C, et al. Value of Multiparametric US in the Assessment of Intratesticular Lesions. Radiology. 2017;285(2):640-649. doi:10.1148/radiol.2017161373
Gilligan TD, Seidenfeld J, Basch EM, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388-3404. doi:10.1200/JCO.2009.26.4481
Testicular Cancer EAU Guidelines On.; 2024.
Feldman DR, Lorch A, Kramar A, et al. Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group. J Clin Oncol. 2016;34(4):345-351. doi:10.1200/JCO.2015.62.7000
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi:10.3322/caac.21388
Gillessen S, SauvéSauv N, Collette L, et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Vol 39.; 2021. https://www.eortc.org/IGCCCG-Update
International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594-603. doi:10.1200/JCO.1997.15.2.594
Huddart RA, O’Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25(21):3090-3095. doi:10.1200/JCO.2006.09.3831
Salem M, Gilligan T. Serum tumor markers and their utilization in the management of germ-cell tumors in adult males. Expert Rev Anticancer Ther. 2011;11(1):1-4. doi:10.1586/era.10.219
Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol. 2000;163(3):796-801.
Lempiäinen A, Hotakainen K, Blomqvist C, Alfthan H, Stenman UH. Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma. Clin Chem. 2007;53(8):1560-1561. doi:10.1373/clinchem.2007.088518
Gilligan T, Aggarwal R, UCSF Helen Diller Family Þ, et al. NCCN Guidelines Version 1.2025 Testicular Cancer Version.; 2025. https://www.nccn.org/home/member-
Hinz S, Schrader M, Kempkensteffen C, et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol. 2008;179(3):936-940; discussion 940. doi:10.1016/j.juro.2007.10.054
Wagner T, Toft BG, Lauritsen J, et al. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study. Eur J Cancer. 2024;202. doi:10.1016/j.ejca.2024.114025
Beyer J, Albers P, Altena R, et al. Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer. Annals of Oncology. 2013;24(4):878-888. doi:10.1093/annonc/mds579
Busch J, Schmidt S, Albers P, et al. Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. World J Urol. 2022;40(12):2843-2852. doi:10.1007/s00345-022-03931-6
Fischer S, Rothermundt C, Stalder O, et al. The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci. 2023;50:57-60. doi:10.1016/j.euros.2023.01.013
Fankhauser CD, Christiansen AJ, Rothermundt C, et al. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer. 2022;126(8):1140-1144. doi:10.1038/s41416-021-01643-z
Mortensen MS, Bandak M, Kier MGG, et al. Surveillance versus adjuvant radiotherapy for patients with high-risk stage I seminoma. Cancer. 2017;123(7):1212-1218. doi:10.1002/cncr.30458
Vesprini D, Chung P, Tolan S, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer. 2012;118(21):5245-5250. doi:10.1002/cncr.27539
Joffe JK, Cafferty FH, Murphy L, et al. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199
Tolan S, Vesprini D, Jewett MAS, et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol. 2010;57(3):474-479. doi:10.1016/j.eururo.2009.06.029
Mead GM, Fossa SD, Oliver RTD, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103(3):241-249. doi:10.1093/jnci/djq525
Wagner T, Toft BG, Lauritsen J, et al. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study. Eur J Cancer. 2024;202. doi:10.1016/j.ejca.2024.114025
De La Pena H, Sharma A, Glicksman C, et al. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. Eur J Cancer. 2017;84:354-359. doi:10.1016/J.EJCA.2017.07.005
Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. Adv Urol. 2018;2018. doi:10.1155/2018/8671832
Chovanec M, Lauritsen J, Bandak M, et al. Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nat Rev Urol. 2021;18(4):227-245. doi:10.1038/s41585-021-00440-w
Wanderås EH, Fosså SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer. 1997;33(2):253-262. doi:10.1016/S0959-8049(96)00458-3
